1.Diffuse large B-cell lymphoma with pulmonary cryptococcosis: report of 1 case and review of literature
Caiqin LIN ; Suli WANG ; Shaoying PAN ; Dongsheng XIE ; Miaomiao TIAN ; Leina SONG ; Huijun LING ; Huizhen SHI ; Bin ZHU ; Zhiyong DING ; Wenli ZHAO
Journal of Leukemia & Lymphoma 2025;34(3):155-158
Objective:To improve the understanding of patients with diffuse large B-cell lymphoma (DLBCL) with pulmonary cryptococcosis.Methods:The clinical data of 1 DLBCL patient with pulmonary cryptococcosis in the Central Hospital of Fengxian District of Shanghai in May 2023 were retrospectively analyzed, and the relevant literatures were reviewed.Results:This 75-year-old female patient was asymptomatic after 2 cycles of R-CHOP chemotherapy. The high-resolution CT of lung showed that lung nodules were progressively enlarged. Antibacterial treatment was ineffective. Pulmonary cryptococcosis was confirmed by bronchoalveolar lavage fluid (BALF) targeted high-throughput sequencing (tNGS) and cryptococcus capsular antigen (CrAg) detection. The central nervous system was not involved. And the long-term adequate-dose fluconazole was prescribed for 6 months, and the treatment against lymphoma was given synchronously. The lung nodule lesions reduced after antifungal therapy for 1 month. The lung nodules disappeared after the follow-up of 6 months after completion of final chemotherapy. The evaluation of lymphoma indicated complete remission.Conclusions:Pulmonary cryptococcosis occurs insidiously and shows no specific symptoms; its imaging manifestations are variable and routine anti-infection is ineffective. Immunochemotherapy for lymphoma patients is a high-risk factor for cryptococcal infection. tNGS and CrAg testing for BALF are effective methods of the confirmed diagnosis. The early and long-term adequate-dose antifungal treatment is the key to preventing the recurrence or progression.
2.Experimental studies on apoptosis imaging of 153Sm-Annexin V
Jiang LIU ; Yingru ZHAO ; Jian WANG ; Leina SUN ; Ruifang NIU ; Wengui XU
Chinese Journal of Clinical Oncology 2013;(12):690-693
10.3969/j.issn.1000-8179.2013.12.002
3.Clinical Analysis of 22 Cases of Basaloid Squamous Carcinoma
Lei WANG ; Lei ZHANG ; Qiuli WU ; Xuefeng KAN ; Zhongli ZHAN ; Leina SUN ; Hong ZHU ; Changli WANG
Chinese Journal of Clinical Oncology 2010;37(5):280-283
Objective: To discuss the clinical features of basaloid squamous carcinoma(BSC)and the factors relating to its prognosis and to compare patient survival between poorly differentiated squamous cell carcinoma(PDSC)and BSC. Methods: Clinical and pathological data of BSC and PDSC cases seen in our hospital between January 2004 and December 2008 were reviewed. Results: There were no statistical differences in demographic and clinical features between PDSC and BSC patients,with the exception that a larger proportion of BSC patients were female(P=-0.001).Additionally,higher tobacco consumption was observed among BSC male patients (P=0.003).There were no significant differences in survival rate between BSC and PDSC groups(X2=0.03,P=0.5470).The median survival time of BSC and PDSC patients was 19 months and 30 months,respectively.The 4-year survival rate was 22.4%and 36.1%,respectively(u=0.740,P=0.230).No significant difference was found in survival rate between stage Ⅰ and stage Ⅱ patients(X~2=0.109,P=0.2974).The median survival time of stage Ⅰ and stage Ⅱ patients was 19 months and 46 months,respectively;and the 4-year survival rate of stage Ⅰ and stage Ⅱ patients was 47.3% and 45.2%,respectively(u=0.122,P=0.450).Using Cox proportional hazard model,we found that surgical types and clinical stages of BSC were correlated with its prognosis.Compared with that of patients who received lobectomy,the postoperative mortality hazard of patients who received pneumonectomy and segmentectomy was increased by 1.379 times(P=0.031)and 1.634 times(P=0.061),respectively.A more advanced clinical stage was associated with an increase in the postoperative morta,ty hazard ratio(X~2=14.12,P=0.000).The postoperative mortality hazard of patients of stage Ⅲ and stage Ⅳ was 2.437 times higher than that of stage Ⅰ patients(P=0.018).There were no statistical differences in postoperative mortality risk between stage Ⅰ patients and stage Ⅱ patients(P=0.057). Conclusion: Compared with that of PDSC,the incidence of BSC is higher among females.However,there is no difference in the prognosis between BSC and PDSC.BSC can be treated with the same therapies as those for other types of non-small cell lung cancer(NSCLC).
4.The Expression and Clinical Significance of C-kit、C-abl and PDGFR? in Ovarian Carcinoma
Leina WANG ; Xiaoyu TIAN ; Jianqiang MI ; Yunhong GUO ; Lili XIONG ;
Journal of Medical Research 2006;0(08):-
Objective This study was to examine the expression of tyrosine kinase receptor(TKRs)C-kit,C-abl and PDGFR?,in ovary carcinoma.Methods The expression of C-kit,C-abl and PDGFR? in tumor tissue of 60 specimens of ovary carcinoma and normal fissue of 20 specimens of overy was examined by immunohistochemistry SP method.Results Immunoreactivity was detected in 79% of the tumor to at least one TKR.The total positive expression rate of C-kit,C-abl and PDGFR? in ovary carcinoma was 58.3%,70%,73.3%,respectively.The positive expression rate of C-kit and PDGFR? is significantly higher in tumor tissues than in normal tissues(P

Result Analysis
Print
Save
E-mail